Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Cancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
J Clin Invest. 2023 Nov 1;133(21):e174171. doi: 10.1172/JCI174171.
Although subsets of patients with lung squamous cell carcinoma (LSCC) benefit from immunotherapy, there are few effective molecularly targeted treatments for LSCC. Fibroblast growth factor receptor (FGFR) inhibitors provide a therapeutic option for patients with LSCC harboring FGFR aberrations, but their therapeutic efficacy has been limited to date. In this issue of the JCI, Malchers et al. identified tail-to-tail rearrangements, either within or near FGFR1, that are associated with FGFR1 dependency and sensitivity to FGFR inhibition in LSCC. These results may help improve the selection of patients with LSCC who are most likely to benefit from treatment with FGFR inhibitors.
尽管肺鳞状细胞癌（LSCC）的部分患者受益于免疫疗法，但针对 LSCC 的有效分子靶向治疗方法却寥寥无几。成纤维细胞生长因子受体（FGFR）抑制剂为携带 FGFR 异常的 LSCC 患者提供了一种治疗选择，但迄今为止，其治疗效果一直受到限制。在本期 JCI 中，Malchers 等人鉴定出 FGFR1 内或附近的 FGFR1 尾对尾重排，这些重排与 LSCC 中 FGFR1 的依赖性以及对 FGFR 抑制的敏感性相关。这些结果可能有助于提高 FGFR 抑制剂治疗最有可能受益的 LSCC 患者的选择。
